𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemotherapy in thymoma and myasthenia gravis

✍ Scribed by P. A. Kosmidis; E. Iliopoulos; S. Pentea

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
519 KB
Volume
61
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Malignant thymoma (MT) is a rare tumor that is often associated with myasthenia gravis (MG). This tumor is considered resistant to chemotherapy. We had the opportunity to treat five patients with MT with cyclophosphamide 800 mg/m2, Adriamycin 50 mg/m2, and vincristine 1.4 mg/m2 (CAV) in cycles of 21 days. Two patients with MG that was resistant to antimyasthenic drugs immediately responded to this combination. One patient with only MT had a complete response, and two patients with only MT had a partial response. Two out of the five patients are still alive and free of disease. Two patients died of disease, and one died from a neutropenia-induced respiratory tract infection. It is concluded that this combination chemotherapy is active in MT and MG and deserves additional trials.

πŸ“œ SIMILAR VOLUMES

Invasive thymoma with myasthenia gravis
Invasive thymoma with myasthenia gravis
✍ Yasumasa Monden; Kazuya Nakahara; Satoru Nanjo; Yoshitaka Fujii; Akihide Matsumu πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 516 KB
Disseminated thymoma and myasthenia grav
Disseminated thymoma and myasthenia gravis: Dramatic rsponde to prednisone
✍ R. Taylor; R. Tandan; J. Roberts; D. P. Dicostanzo; K. Sharma; T. Fries πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 435 KB

Myasthenia gravis (MG) occurs in up to 44% of patients with thymoma; one-third of neoplasms are invasive at surgery {I}, and 1 to 15% show extrathoracic metastases [2}. The prognosis in patients having MG with invasive thymoma is worse. Thymectomy and radiotherapy are the mainstays of treatment for